ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

After Array BioPharma (NASDAQ: ARRY) announced quarterly results and shared some clinical news with investors on Tuesday, shares of the cancer-focused clinical-stage biotech jumped and were up 18% as ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. Ron Squarer, Chief Executive Officer of Array, noted, ...

Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (NASDAQ: ARRY) 115% in 2016. However, after a string of successes, Array hit a setback earlier this week: ...

* Says revenue for q2 of fiscal 2017 was $44.5 million, compared to $39.3 million for prior sequential quarter * Says revenue for q2 of fiscal 2017 increased $9.1 million compared to same quarter of ...